-

Ferring Pharmaceuticals announces optimisation of operations to accelerate growth
in STATEMENT 2025 on -

Ferring announces new Ambition, Enterprise Model and Executive Committee composition to accelerate growth and innovation
in STATEMENT 2025 onFerring announces new Ambition, Enterprise Model and Executive Committee composition to accelerate…
-
Ferring Statement on Minirin® / Octostim® / DDAVP® / Stimate® (desmopressin) Nasal Spray
in STATEMENT 2025, STATEMENT 2022 onFollowing the detection of out-of-specification results during testing, in 2020 Ferring initiated a precautionary voluntary global recall of all batches of the following products: Minirin® (desmopressin) Nasal Spray 0.1 mg/ml…
STATEMENT 2025
STATEMENT 2025